Leaders Insights
Leaders Insights

Rester au meilleur niveau, un peu chaque jour.

DomainesMarketingDataFinanceIA
RessourcesApprendreTestOutilsBlogGlossaire
© 2026 Leaders Insights — Tous droits réservés.
Formations/AI in FMCG/Use cases, ROI and evaluation/Governing AI risk in claims, labels and consumer-facing content
5/5+150 XP

Use cases, ROI and evaluation

5Where AI creates value across the FMCG chain+1506Spotting AI-washing in vendor pitches+1507Piloting AI on the plant floor and in trade promotions+1508Building a defensible ROI case for AI investment+1509Governing AI risk in claims, labels and consumer-facing content+150

Governing AI risk in claims, labels and consumer-facing content

# Governing AI risk in claims, labels and consumer-facing content

A snack brand's marketing team used a generative AI tool to draft new packaging copy. The AI suggested the phrase "clinically proven to boost immunity" for a fruit snack with added vitamin C. Nobody on the team had run a clinical trial. The copy went through design approval, got printed on thousands of units, and shipped. Within weeks, a regulator flagged it as an unsubstantiated health claim. The recall, relabeling, and reputational cleanup cost far more than the campaign's entire production budget.

This is not a hypothetical edge case. It is the predictable failure mode of using generative AI for claims and labels without governance. This lesson builds the checklist that prevents it.

Why FMCG labeling is uniquely high-risk for generative AI

Fast-moving consumer goods (FMCG) companies ship enormous volumes of consumer-facing text: package copy, nutrition claims, allergen statements, marketing emails, social captions, ingredient descriptions. Generative AI (large language models, or LLMs, that produce human-like text on demand) is attractive here because it speeds up drafting at scale across hundreds of SKUs (stock keeping units, the individual product-variant codes a retailer tracks) and dozens of markets.

But three features of this content make it dangerous territory for unsupervised AI:

It is regulated speech, not just marketing copy. Health and nutrition claims are governed by specific legal regimes, not general advertising standards.

It is printed and distributed at scale before anyone can easily intervene. Unlike a website, you cannot "un-publish" a printed carton once it is on a truck.

LLMs are fluent, not factual.

They generate plausible-sounding claims ("clinically proven," "doctor recommended," "detoxifies") because those phrases are statistically common in training data, not because the model verified anything. This is the well-documented tendency called hallucinationhallucinationA hallucination is when an AI model generates output that is fluent and confident but factually wrong, fabricated, or unsupported by its source data.Voir la définition complète →: confident output that is fabricated or unsupported.

The regulatory landscape you must design around

In the United States, the Food and Drug Administration (FDA) regulates food labeling and health claims under the Food, Drug, and Cosmetic Act, and the Federal Trade Commission (FTC) polices deceptive advertising claims more broadly. The FDA maintains a specific, narrow list of approved health claims (for example, calcium and osteoporosis risk); anything outside that list needs careful qualification or it risks being deemed a misbranded product. See the FDA's guidance on food labeling and claims for the authoritative source.

In the European Union, the Nutrition and Health Claims Regulation (EC) 1924/2006 requires that any health or nutrition claim be pre-authorized and listed in the EU Register of nutrition and health claims, maintained by the European Food Safety Authority (EFSA). Unauthorized claims like "boosts immunity" without a registered, specific basis are enforcement targets across EU member states.

Both regimes share a core principle: the burden of proof sits with the brand, not the regulator. If your AI tool writes it and your team publishes it, your company owns the liability, not the AI vendor.

Where generative AI genuinely helps in this workflow (and where it doesn't)

Good fit:

  • Drafting first-pass variations of *already-approved* claims for A/B testingA/B testingA/B testing is a controlled experiment that compares two versions of something (A and B) by splitting traffic randomly to learn which performs better on a chosen metric.Voir la définition complète → in digital ads
  • Translating and localizing approved copy across markets (with human legal review per locale)
  • Summarizing ingredient panels into consumer-friendly language, checked against source data
  • Generating internal briefing documents or competitive claim scans

Poor fit without heavy guardrails:

  • Originating new health, nutrition, or efficacy claims from scratch
  • Any claim involving comparative superiority ("more effective than leading brand")
  • Allergen or safety statements
  • Anything destined directly for print with no human legal sign-off

The pattern: AI is strong at *variation and translation of vetted content*, weak at *originating regulated factual claims*.

Building the pre-deployment review checklist

A usable checklist has to mapmapUsing software to automate repetitive marketing tasks and campaigns, enabling personalisation at scale across channels like email, web, and social.Voir la définition complète → to where failures actually occur: model input, model output, and organizational process.

1. Source-of-truth control

Does the AI tool draw only from an approved, curated database of claims and product facts, or does it freely generate from general training data? Tools built on retrieval-augmented generation (RAG, a technique where the model is restricted to pulling facts from a specific approved document set rather than its general knowledge) are meaningfully safer for claims work than an open general-purpose chatbot.

2. Claim provenance tagging

Every AI-suggested claim should be tagged with its source: is it from the EFSA register, an FDA-approved list, or the model's own generation? If provenance cannot be shown, treat the claim as unverified.

3. Human-in-the-loop sign-off gates

Legal or regulatory affairs review is mandatory before any AI-drafted claim moves to design or print, no exceptions for "minor" copy changes. Minor changes ("boosts" versus "supports") can shift legal meaning entirely.

4. Version and audit trail

Keep a log of which AI tool, version, and prompt generated which piece of copy, and who approved it. Regulators and internal audit will ask "how did this get approved" after any incident; you need an answer.

5. Red-team testing before rollout

Before deploying a tool company-wide, deliberately prompt it with edge cases: "write an aggressive health claim for this snack," "compare this product favorably to a named competitor." If it complies too readily, it needs stricter guardrails or a different tool.

6. Market-specific configuration

A claim compliant in the US may be non-compliant in the EU or UK (which has its own post-Brexit regime via the Food Standards Agency). AI tools must be configured per market, not globally.

7. Allergen and safety statement exclusion

These should never be AI-generated from scratch. Treat them as fixed, legally-sourced fields pulled from verified product databases, not creative text.

# Simplified pseudocode for a claim-check gate in a content pipeline

def check_claim(draft_text, market, claims_db):
    matched = claims_db.lookup(draft_text, market)
    if not matched:
        return "BLOCK: unverified claim, route to legal review"
    if matched.status != "approved_for_market":
        return "BLOCK: claim not approved in this market"
    return "PASS: log claim_id, source, approver, timestamp"

This is illustrative, not production code, but it captures the principle: claims should hit a database check, not just a fluency check.

Vérification des acquis

1. Why did the generative AI tool produce the unsubstantiated claim 'clinically proven to boost immunity' for the fruit snack?

2. What is the key distinction that makes health and nutrition claims a different risk category than general marketing copy?

3. A packaging team wants to use generative AI to speed up drafting ingredient descriptions across 300 SKUs in multiple markets. Based on the lesson, what is the most appropriate governance approach?

CHOIX MULTIPLES

4. Select ALL correct answers describing why FMCG labeling is uniquely high-risk territory for unsupervised generative AI use.

Sélectionnez toutes les réponses correctes.

CHOIX MULTIPLES

5. Select ALL correct answers that reflect an accurate understanding of 'hallucination' as used in this lesson.

Sélectionnez toutes les réponses correctes.

Evaluating vendors: questions that separate real governance from marketing

When an AI vendor pitches a "content generation for FMCG" tool, ask:

  • Can the system restrict outputs to a client-managed approved-claims library (RAG-based), or does it generate freely from general web-scale training data?
  • What audit logs does it produce, and can they be exported for a regulatory inquiry?
  • Does it support market-specific rule sets (EU claims register vs. FDA list vs. UK FSA)?
  • What is its documented hallucinationhallucinationA hallucination is when an AI model generates output that is fluent and confident but factually wrong, fabricated, or unsupported by its source data.Voir la définition complète → rate on factual/claims tasks, and how was that measured (ask for methodology, not just a headline percentage)?
  • Who is contractually liable if the tool outputs a non-compliant claim: the vendor or you? (In practice, regulatory liability almost always sits with the brand regardless of contract terms, so this is about internal risk allocation and vendor accountability, not regulatory defense.)

Treat vague answers as a red flag. A vendor that cannot describe its guardrail architecture is not ready for regulated content.

🎬 [VIDEO: "How the FDA Regulates Food Labels" - youtube.com/@usfoodanddrugadmin - an FDA overview of the label review process, useful context for where AI-drafted content must plug into human regulatory review]

Key Takeaways

  • Generative AI can hallucinate confident-sounding health and nutrition claims; in FMCG labeling this is a regulatory liability, not just an accuracy nuisance.
  • US claims fall under FDA and FTC rules; EU claims require pre-authorization under Regulation (EC) 1924/2006 via the EFSA register. Liability sits with the brand, not the AI vendor.
  • The safest AI use cases are variation and localization of already-approved copy, not origination of new factual or health claims.
  • A deployment checklist needs source-of-truth control, provenance tagging, mandatory human sign-off, audit trails, red-team testing, and market-specific configuration.
  • When evaluating vendors, prioritize retrieval-restricted (RAG) architectures and clear audit logging over generic fluency demos.

Précédent

Building a defensible ROI case for AI investment